Genna Guedon
Family · Natchez, MSNPI 1285074369
Payments from drug & device makers
Across 202 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$635
- GSK$420
- AstraZeneca$418
- Merck$410
- AbbVie$293
- Johnson & Johnson$196
- plus $1K from 14 others
What the payments were for
- Food & beverage$3,501100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 36 | $635 |
| GSK | 23 | $420 |
| AstraZeneca | 26 | $418 |
| Merck | 23 | $410 |
| AbbVie | 16 | $293 |
| Johnson & Johnson | 11 | $196 |
| Pfizer | 11 | $186 |
| Lilly USA, LLC | 9 | $166 |
| Sanofi-aventis U.S. LLC | 11 | $152 |
| Amgen | 9 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $128 |
| Novo Nordisk | 6 | $92 |
| Astellas Pharma US Inc | 5 | $81 |
| Bayer | 4 | $65 |
| Vertex | 1 | $24 |
| Exact Sciences | 1 | $20 |
| Mylan Specialty L.p. | 1 | $19 |
| Abbott | 1 | $18 |
| Novartis | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
How this compares
$3,501 in reported general payments places this provider in the 85th percentile of 3,007 family providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $55,952 |
| JardianceEmpagliflozin | 41 | $44,144 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $37,834 |
| FarxigaDapagliflozin Propanediol | 31 | $35,722 |
| LinzessLinaclotide | 17 | $22,475 |
| MyrbetriqMirabegron | 18 | $19,078 |
| EliquisApixaban | 16 | $18,205 |
| TradjentaLinagliptin | 11 | $16,087 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $12,079 |
| GemtesaVibegron | 20 | $9,449 |
| Atorvastatin Calcium | 215 | $1,991 |
| Amlodipine Besylate | 291 | $1,711 |
| Valsartan | 50 | $1,433 |
| Levothyroxine Sodium | 130 | $1,429 |
| Famotidine | 74 | $1,242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $635 | $60,23152 claims |
| GSKTrelegy Ellipta | $420 | $55,95243 claims |
| AstraZenecaFarxiga | $418 | $35,72231 claims |
| AbbVieLinzess | $293 | $22,47517 claims |
| Astellas Pharma US IncMyrbetriq | $81 | $19,07818 claims |
| PfizerEliquis | $186 | $18,20516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,007 family providers in Mississippi.
Other family in Natchez
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
- Ashley CocilovaFlowood$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.